Pennington Biomedical Researchers to Present at the ADA’s 2026 Scientific Sessions in New Orleans

June 3, 2026 · Baton Rouge, LA

---

Leading experts to reveal groundbreaking research, innovative technologies and transformative approaches in obesity, early detection and diabetes treatment 

Researchers from LSU’s Pennington Biomedical Research Center are scheduled to present their latest findings in diabetes research and treatment at the American Diabetes Association’s (ADA) flagship conference, the 86th annual Scientific Sessions, taking place June 5-8 in New Orleans.

The ADA’s Scientific Sessions is the world’s largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers and healthcare professionals from around the globe. The premier diabetes meeting will feature the latest scientific findings in diabetes and obesity. Leading experts will share findings from research on prevention, care and cures at the Ernest N. Morial Convention Center.  

Over 40 million Americans are living with diabetes, and as rates continue to climb, this year’s sessions will spotlight the latest cutting-edge advancements driving progress in diabetes and obesity research and management.  

Key themes of this year’s sessions include: 

• Advancing obesity treatment and metabolic health: Clinical studies showcase next-generation therapies and treatment strategies for obesity and diabetes, including incretin-based approaches and their effects on weight, glycemic management and long-term metabolic health.
• Prevention, early detection and disease modification: New research highlights innovative strategies to identify diabetes earlier and intervene more effectively, including advances in biomarkers, precision medicine and lifestyle interventions that can delay or prevent disease progression.
• Improving cardiometabolic outcomes: Emerging evidence examines how new therapies are transforming outcomes related to the heart, kidney and liver, reducing complications and improving longevity for people living with diabetes.
• Transforming care through innovation and access: New research highlights how technology, artificial intelligence and implementation strategies are reshaping diabetes care – reducing treatment burden, expanding access and enabling more person-centered care.
• Advancing beta cell replacement and cure strategies: Cutting-edge science explores advances in beta cell replacement, regenerative medicine and immune-based therapies aimed at achieving long-term remission or cure.

Researchers from Pennington Biomedical will present their latest findings through oral presentations, symposiums, debates and poster sessions at the conference.

“Pennington Biomedical is proud to contribute to the American Diabetes Association’s 2026 Scientific Sessions, alongside fellow leading researchers from around the world,” said Dr. Jennifer Rood, Interim Senior Vice Chancellor and Executive Director. “The breadth of research being presented reflects our continued commitment to discovery, collaboration and translating science into meaningful health outcomes for patients and communities.”

Poster presentations will feature research from Heidi Batdorf, Dr. Wentao Cao, Dr. Ji Suk Chang, Victoria Maria Datta, Dr. Carrie Elks, Elizabeth Heintz, Dr. Peter Katzmarzyk, David Mendoza, Dr. Hongyan Sun, Aleah Verret, Lindsey Yoo.

Featured sessions include Dr. Eric Ravussin and Dr. Donna Ryan participating in the debate “Muscle Loss in GLP-1 Receptor Agonist–Induced Weight Loss: A Real Concern or Much Ado about Nothing?”; Dr. Heike Munzberg presenting “Humoral Interoception: Leptin Circuits and Energy Homeostasis”; and Dr. Melinda Stephens presenting “Metabolic Programming during Development and Aging.”

Oral presentations will include Analisa Taylor’s “Impaired Skeletal Muscle Insulin Signaling Drives MIRO1 Accumulation and Defective Mitochondrial AKT Translocation” and Dr. Thomas Martin’s “Elevated Interferon-Gamma Response Signatures Observed at Single-Cell Resolution in Islet Beta Cells from Donors with Type 1 Diabetes.”

Learn more about the ADA’s 2026 Scientific Sessions. For more information, please email the ADA’s Scientific Sessions press team at SciSessionsPress@diabetes.org.